CD72 Negatively Regulates KIT-Mediated Responses in Human Mast Cells

Tatsuki R. Kataoka, Atsushi Kumanogoh, Geethani Bandara, Dean D. Metcalfe and Alasdair M. Gilfillan

*J Immunol* published online 25 January 2010
http://www.jimmunol.org/content/early/2010/01/25/jimmunol.0902450

---

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
CD72 Negatively Regulates KIT-Mediated Responses in Human Mast Cells

Tatsuki R. Kataoka,*† Atsushi Kumanogoh,‡ Geethani Bandara,*, Dean D. Metcalfe,* and Alasdair M. Gilfillan*

KIT activation, through binding of its ligand, stem cell factor, is crucial for normal mast cell growth, differentiation, and survival. Furthermore, KIT may also contribute to mast cell homing and cytokine generation. Activating mutations in KIT lead to the dysregulated mast cell growth associated with the myeloproliferative disorder, mastocytosis. We investigated the potential of downregulating such responses through mast cell inhibitory receptor activation. In this study, we report that the B cell-associated ITIM-containing inhibitory receptor, CD72, is expressed in human mast cells. Ligation of CD72 with the agonistic Ab, BU40, or with recombinant human CD100 (rCD100), its natural ligand, induced the phosphorylation of CD72 with a resulting increase in its association with the tyrosine phosphatase SH2 domain-containing phosphatase-1. This, in turn, resulted in an inhibition of KIT-induced phosphorylation of Src family kinases and extracellular-regulated kinases (ERK1/2). As a consequence of these effects, KIT-mediated mast cell proliferation, chemotaxis, and chemokine production were significantly reduced by BU40 and rCD100. Furthermore, BU40 and rCD100 also downregulated the growth of the HMC1.2 human mast cell line. Thus, targeting CD72 may provide a novel approach to the suppression of mast cell disease such as mastocytosis. The Journal of Immunology, 2010, 184: 000–000.

Abbreviations used in this paper: β-hex, β-hexamimidine; huMC, human mast cell; MAFa, mast cell function-associated Ag; rCD100, recombinant human CD100; SCF, stem cell factor; SFK, Src family member tyrosine kinases; SHP, Src homology domain-containing inositol 5-phosphatase; SHP, Src homology domain-containing tyrosine phosphatase; Stat3, signal transducers and activators of transcription 3.

*Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; †Department of Pathology, Hyogo College of Medicine, Nishinomiya, Hyogo; ‡Department of Immunopathology, Research Institute for Microbial Diseases; and WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Received for publication July 28, 2009. Accepted for publication December 28, 2009.

This work was supported by the National Institute of Allergy and Infectious Diseases Division of Intramural Research within the National Institutes of Health, United States, and by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

Address correspondence and request reprints to Dr. Tatsuki R. Kataoka at the current address: Department of Pathology, Hyogo College of Medicine, 1-1, Mukogawa, Nishinomiya, Hyogo, 663-8501, Japan. E-mail address: trkataoka@yahoo.co.jp

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0902450
CD72–SHP-1 complex. Thus, downregulation of KIT-mediated responses through CD72 may provide a potential means for the control of mast cell-driven disorders.

Materials and Methods

Cells

The huMCs, derived from CD34-positive peripheral blood cells, were cultured in StemPro-34 medium with supplement (Invitrogen, Carlsbad, CA), containing t-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL), recombinant human SCF (100 ng/mL, Peprotech, Rocky Hill, NJ), and recombinant human IL-6 (100 ng/mL, Peprotech) as before (15). The human LAD2 mast cell line was cultured in StemPro-34 with supplement containing t-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 μg/mL), and recombinant human SCF (100 ng/mL, Peprotech) (16). HMC1.1 (expresses VS60G KIT) and HMC1.2 (expresses VS60G and D816V KIT) huMC lines were grown in IMDM medium supplemented with FBS (10%), t-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 μg/mL) (5, 17, 18). The U937 monocyctic cell line and the Raji human B cell line were purchased from American Type Culture Collection (Manassas, VA), and grown in RPMI 1640 medium supplemented with FBS (10%), t-glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 μg/mL).

Recombinant CD100 and Abs

Recombinant CD100 (rCD100) protein was prepared as described (19). The anti-human CD72 Ab BU40 (monoclonal, mouse IgG) was purchased from Southern Biotechnology Associates (Birmingham, AL). The anti-CD72 Ab H-96 (rabbit polyclonal IgG) and anti–SHP-1 Ab (C-19, rabbit polyclonal IgG) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phosphotyrosine Ab (4G10, mouse monoclonal IgG) was purchased from Millipore (Billerica, MA). Anti–phospho-KIT (Tyr 703) Ab (rabbit polyclonal IgG) was purchased from Invitrogen. Anti–phospho-Src (Tyr 416) and anti–phospho-ERK Ab (both were rabbit polyclonal IgG) were obtained from Cell Signaling Technology (Beverly, MA). Anti–β-actin Ab (mouse monoclonal IgG) was obtained from Sigma-Aldrich (St. Louis, MO). Isotype control Abs were obtained from BD Biosciences (San Jose, CA) and the secondary Abs were peroxidase-labeled-anti-rabbit or anti-mouse IgG Abs from Santa Cruz Biotechnology.

Immunoblotting and immunoprecipitation

Cell lysates were prepared, the proteins separated by electrophoresis, and gels probed for immunoreactive proteins as described (20). Immunoprecipitation experiments were executed using an anti-CD72 Ab H-96 or anti–SHP-1 Ab (C-19) as described (19). The cells were lysed with buffer containing 150 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM aprotinin, 5 μg/mL leupeptin, Complete protease inhibitor cocktails (Roche, Indianapolis, IN), and NP-40 (1%). The cell lysates were incubated with rabbit IgG-bound protein G-Sepharose for 30 min, then incubated with anti-CD72 Ab (H-96)-bound or anti–SHP-1 Ab (C-19)-bound protein G-Sepharose overnight at 4˚C with rotation.

RT-PCR

Total RNA was extracted from 5 × 10⁶ cells (huMCs at various times of culture, LAD2, HMC1.1, HMC1.2, U937, and Raji). Cells were lysed with Trizol (Invitrogen) and RNA was extracted using Rneasy Mini Kit (Qiagen, Valencia, CA). CDNA was synthesized and amplified using SuperScript III One-Step RT-PCR System (Invitrogen). One microgram of RNA was used for cDNA synthesis. A 834-bp region of CD72 gene between exon 1–6 was amplified using the primers 5′-ATGGCTGAGGCCATACCTA-3′ and 5′-TGATTGTTGGAATATTTCACTGAT-3′ and a 998-bp fragment between exon 2–8 was amplified using primers 5′-ACCCAGGGCTGATTGAT-3′ and 5′-CTAATCTGGAAACCTGAGCTG-3′. cDNA synthesis and PCR amplification were performed with a DNA Engine PTC200 cycler (Bio Rad Laboratories, Hercules, CA) with the following thermal cycle protocol: 50˚C for 30 min, 94˚C for 2 min, followed by 30 cycles of 94˚C for 30 s, 60˚C for 1 min, 72˚C for 1 min, and a final extension of 10 min at 72˚C.

Flow cytometry

For the detection of CD72 surface expression, huMCs, LAD2, HMC1.1, or HMC1.2 cells were washed with PBS, and fixed with 4% paraformaldehyde (Sigma-Aldrich). The cells were stained with anti-human CD72 (BU40) overnight at 4˚C, followed by anti-mouse IgG-FITC for 2 h at 4˚C. The cells were then analyzed using a FACSScan flow cytometer.

Cell cycle analysis

Cell cycle progression of huMCs or HMC1.2 was analyzed as described (21). Briefly, huMCs or HMC1.2 cells were cultured overnight in cytokine-free medium, and resuspended in HEPES buffer containing 0.04% BSA (huMCs) or IMEM and 10% PBS (HMC1.2). After 30 min preculture, 10 ng/mL SCF was added and the cells cultured for 30 min with or without control IgG, BU40, or rCD100 (10 μg/mL, respectively). The cells were fixed with 100% ethanol, treated with RNase A (Roche), and stained with propidium iodine (Sigma-Aldrich) for 2 h at 4˚C. The cells were then analyzed using a FACSScan flow cytometer.

BrdU cell proliferation assay

Cell proliferation was determined by the BrdU (an analog of thymidine) assay that measures its incorporation into DNA. HuMCs were incubated with BrdU for 24 h at 1.5 × 10⁵ cells/100 μL in 96-well plates with PBS with 0.1% Na3SCF, PBS and 0.1% Na3SCF, and control IgG (10 μg/mL), PBS and BU40 (10 μg/mL), or SCF and rCD100 (10 μg/mL) (SCF; 10 ng/mL, respectively). HMC1.2 cells were cultured overnight in IMEM without PBS, then resuspended in IMEM containing 10% FBS. HMC1.2 cells were then incubated for 24 h at 1.5 × 10⁵ cells/100 μL in 96-well plates with PBS with 0.1% Na3N3, control IgG (10 μg/mL), BU40 (10 μg/mL), or rCD100 (10 μg/mL). Incorporation of BrdU into the huMCs or HMC1.2 cells was assessed using a BrdU cell proliferation assay kit (Calbiochem, San Diego, CA) as previously described (21).

Chromotaxis assay

Chromotaxis was assessed using transwell polycarbonate membranes (8 μm pores, Costar, Cole-Parmer, Vernon Hills, IL) as described (20). Briefly, 1 × 10⁶ huMCs were cultured overnight in cytokine-free medium, and resuspended in HEPES buffer containing 0.5% BSA. PBS with 0.1% Na3N3, control IgG (10 μg/mL), BU40 (10 μg/mL), or rCD100 (10 μg/mL) was added to the cell suspension (1 × 10⁷/100 μL), then the cells placed in the upper chamber. The upper chambers were placed in lower chambers containing 600 μL of HEPES buffer with 0.5% BSA for 30 min at 37˚C, then chromotaxis was assessed by placing the upper chambers in a new set of lower chambers containing the same buffer with SCF (30 ng/mL). After 4 h incubation at 37˚C, the cells migrating to the lower wells were collected and counted by microscopy.

MCP-1 (CCL2) secretion

To examine KIT-mediated MCP-1 (CCL2) secretion (22), huMCs were cultured overnight in cytokine-free medium, then resuspended in cytokine-free StemPro-34 medium. A total of 1 × 10⁶ huMCs per 100 μL were cultured for 6 h in the presence of 10 ng/mL SCF with or without control IgG, BU40, or rCD100 (10 μg/mL, respectively). The cell-free supernatants (50 μL) were taken for ELISA assay (human MCP-1 DuoSet ELISA system, R&D Systems, Minneapolis, MN) according to the manufacture’s protocol.

Degranulation assay

Degranulation from huMCs was monitored by β-hexominidase (β-hex) release as previously described (20). HuMCs were sensitized overnight in cytokine-free, supplemented StemPro cell culture medium containing human myeloma IgE (100 ng/mL, Calbiochem, EMD Biosciences, San Diego, CA, biotinylated in the National Institutes of Allergy and Infectious Diseases core facility), in the presence of control IgG, BU40, or rCD100 (10 μg/mL, respectively). After rinsing in HEPES buffer containing 0.04% BSA, the cells were activated in this buffer with staphylin (100 ng/mL, Sigma-Aldrich) with or without SCF (1 ng/mL, respectively), for 30 min. The remaining huMCs per 100 μL were cultured for (5 min) at 4˚C, and the supernatants were aliquoted to 96-well plates for β-hex assay. The remaining cells were lysed by adding 0.1% Triton X-100, then also analyzed for β-hex content. Degranulation was calculated as percentages of total β-hex content found in the supernatants after challenge.

Statistical analysis

Data were expressed as the mean ± SE. Differences between groups were examined for statistical significance using Student t test. A p value <0.05 indicated statistical significance.

Results

HuMCs express CD72

To first explore whether CD72 is expressed in huMCs, we examined the presence of CD72 mRNA in huMCs and the HMC1.1, HMC1.2, and LAD2 huMC lines. Two sets of primers were designed,
targeting exon 1 to exon 6, or exon 2 to exon 8, of CD72 mRNA. Raji cells (human Burkitt’s lymphoma B cell line) were used as a positive control and U937 cells as a negative control (23). As expected, mRNA for CD72 was found in the Raji cells, but not in the U937 cells (Fig. 1A). CD72 mRNA was also detected in primary cultured huMCs, and in the LAD2, HMC1.1, and HMC1.2 huMC lines, with the size of these transcripts being identical to that of the Raji cells (Fig. 1A). CD72 mRNA was detected at all times during the development of the huMCs cultures. The CD72 mRNA levels of 1- and 2-wk-old cultures were as high as that of HMC1.2 cells. However, the CD72 mRNA levels tended to decrease during subsequent culture periods (Fig. 1B).

To confirm the presence of CD72 in huMCs, we next examined protein expression by immunoblot analysis. These studies verified that CD72 protein is present in the primary cultured huMCs and human tumor mast cell lines, as well as in the Raji control cells (Fig. 1C). The expression of CD72 in the HMC1.1 and HMC1.2 cell lines was greater than the expression levels observed in the mature (8 wk) huMCs and LAD2 cells. Again, CD72 protein was absent in the U937 negative control (Fig. 1C). To establish that CD72 was expressed at the cell surface, we examined surface staining with an anti-CD72 Ab by FACS analysis. As can be seen from Fig. 1D, surface CD72 was detected on both cell types examined; huMCs and HMC1.2 cells.

*Concurrent ligation of CD72 and KIT induces CD72 phosphorylation, SHP-1 recruitment, and SHP-1 phosphorylation*

Members of the ITIM-bearing family of inhibitory receptors mediate their effects through recruitment of the inositol phosphatases SHIP1 and SHIP2 or the tyrosine phosphates SHP-1 and SHP-2 (12). CD72 contains two ITIMs, one of which binds SHP-1 and the other Grb2, when the tyrosine residues within these ITIMs are phosphorylated (24, 25). To examine whether KIT activation induced CD72 phosphorylation or dephosphorylation in mast cells, and whether the phosphorylation status of CD72 was further modified after CD72 ligation, huMCs were stimulated for 5 min with SCF in the absence or presence of BU40 or rCD100. Cell lysates were then prepared, CD72 immunoprecipitated with an anti-CD72 Ab, and the immunoprecipitates probed for phosphotyrosine and the association of SHP-1. Lysates were also immunoprecipitated with a control Ab to assess nonspecific interactions. Using the control Ab for immunoprecipitating, we detected no increase in the tyrosine phosphorylation of CD72 or its association with SHP-1 under any of the experimental conditions described (data not shown).

Using the anti-CD72 Ab for immunoprecipitations, a slight, but detectable, constitutive tyrosine phosphorylation of CD72 was observed under resting conditions (Fig. 2A, 2B). This was associated with a similar slight, but detectable, constitutive association of SHP-1 with CD72 (Fig. 2A, 2B). Challenging the cells with SCF in the absence of BU40 or rCD100 induced minimal change in tyrosine phosphorylation of CD72 and no detectable increase in association of SHP-1 with CD72 (Fig. 2A). When the cells were challenged with SCF in the presence of BU40 or rCD100; however, there was an appreciable increase in tyrosine phosphorylation of CD72 that was linked to a marked enhancement of the association of SHP-1 with CD72 (Fig. 2A). However, when the cells were challenged with BU40 or rCD100 in the absence of SCF, we could not detect a significant change in the level of the phosphorylation of CD72 or the association between CD72 and SHP-1 (Fig. 2B).

**FIGURE 1.** HuMCs and mast cell lines express CD72. A, RT-PCR. B, Western blotting. C, Flow cytometry were performed as described in Materials and Methods. The Raji cells were used as a positive control and the U937 cells as a negative control.

**FIGURE 2.** The effects of BU40 or rCD100 on the tyrosine phosphorylation of CD72, the association of SHP-1 with CD72 and the tyrosine phosphorylation of SHP-1 in huMCs. A, BU40 or rCD100 administration with SCF to huMCs induces the tyrosine phosphorylation of CD72 and the association with SHP-1, whereas (B) BU40 or rCD100 administration in the absence of SCF did not. HuMCs were incubated for 0 or 5 min with control IgG (10 μg/ml), BU40 (10 μg/ml), or rCD100 (10 μg/ml) in the presence or absence of SCF (10 ng/ml). CD72 was immunoprecipitated with anti-CD72 (H-96), and visualized with antiphosphotyrosine 4G10, anti–SHP-1, or anti–SHP-2. C, BU40 or rCD100 administration with SCF (10 ng/ml) to huMCs induces the tyrosine phosphorylation of SHP-1, when incubated for 5 min. SHP-1 was immunoprecipitated with an anti–SHP-1 Ab (C-19), and visualized with antiphosphotyrosine 4G10 or anti–SHP-1. Data are representative of three individual experiments.
Tyrosine phosphorylation of SHP-1 upregulates the phosphatase activity of SHP-1 (26). To assess whether ligation of CD72 induced tyrosine phosphorylation of SHP-1 in addition to recruitment, huMCs were stimulated with SCF concurrently with CD72 ligation, whole cell lysates were immunoprecipitated with an anti–SHP-1 Ab, then the immunoprecipitated proteins probed with an antiphosphotyrosine Ab. Slight tyrosine phosphorylation of SHP-1 was observed under resting conditions (Fig. 2C). However, when the cells were challenged with SCF in the presence of BU40 or rCD100, the tyrosine phosphorylated SHP-1 levels were observed to increase (Fig. 2C).

Taken together, these data provide support for the conclusion that concurrent ligation of CD72 and KIT results in the activation and recruitment of SHP-1 to CD72 with the potential to downregulate KIT-mediated responses in mast cells. We therefore next examined the effects of the CD72 agonistic Ab BU40 and rCD100 on KIT-mediated mast cell function.

**CD72 ligation suppresses KIT-dependent growth of huMCs**

To explore the potential ability of ligated CD72 to downregulate mast cell function, we next examined the effects of the agonistic Ab against human CD72, BU40, or rCD100, on indices of KIT-mediated growth of huMCs. To evaluate the potential role of CD72 in controlling progression through the cell cycle, cytokine-starved huMCs were cultured with SCF for 30 min with or without control IgG, BU40, or rCD100, then the cell cycle status of the cells was assessed by flow cytometry. The proportion of huMCs in G2/M and S phases after a 30-min exposure to SCF was not reduced by control Ab. However, administration of either BU40 or rCD100, together with SCF, resulted in a marked reduction in the ratio of cells in the G2/M and S phases of cell cycle, indicating arrested cell growth (Table I). To provide further support for this conclusion, we examined the abilities of BU40 and rCD100 to inhibit KIT-induced proliferation of huMCs as assessed by BrdU assay. HuMCs were cultured for 24 h in the absence or presence of SCF and control IgG, SCF and BU40, or SCF and rCD100, then the relative growth rates determined. As in the case with cell cycle arrest, both BU40 and rCD100 significantly reduced the growth of huMCs detected in the BrdU assay (Fig. 3A), providing further evidence that ligation of CD72 induces downregulation of KIT-mediated growth of huMCs.

**CD72 ligation downregulates KIT-induced huMC chemotaxis and MCP-1 (CCL2) production**

In addition to regulating cell growth, SCF-dependent KIT activation induces mast cell chemotaxis and the production of MCP-1 (CCL2) (2). We, thus, next investigated the effects of the CD72 agonistic Ab BU40 and rCD100 on KIT-mediated chemotaxis of huMCs.

![FIGURE 3. The effects of BU40 or rCD100 on KIT-mediated responses of huMCs. A. The ligation of CD72 with BU40 or rCD100 suppresses KIT-induced proliferation of huMCs as assessed by BrdU assay. HuMCs cultured for 24 h with or without SCF and control IgG, SCF and BU40, or SCF and rCD100, then the relative growth rates determined. As in the case with cell cycle arrest, both BU40 and rCD100 significantly reduced the growth of huMCs detected in the BrdU assay (Fig. 3A), providing further evidence that ligation of CD72 induces downregulation of KIT-mediated growth of huMCs.](http://www.jimmunol.org/)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Cells in G2/M and S Phases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCF only</td>
<td>6.93 ± 0.58</td>
</tr>
<tr>
<td>SCF and control IgG</td>
<td>7.39 ± 0.85</td>
</tr>
<tr>
<td>SCF and BU40</td>
<td>3.07 ± 0.22*</td>
</tr>
<tr>
<td>SCF and rCD100</td>
<td>3.60 ± 0.44*</td>
</tr>
</tbody>
</table>

* *p < 0.01, when compared with the value of SCF and control IgG.

Table I. Ligation of CD72 with BU40 or rCD100 suppresses KIT-mediated cell cycle progression of huMCs

After overnight culture in cytokine-free medium, huMCs were cultured for 30 min in HEPES buffer containing 0.04% BSA (huMCs) with SCF, SCF and control IgG, SCF and BU40, or SCF and rCD100. The cells were stained with propidium iodine, and then analyzed using a FACScan flow cytometer.
Ag-mediated aggregation of high-affinity receptors for IgE (FcεRI) triggers degranulation of mast cells (1, 2). This response can be further augmented after SCF-dependent KIT activation (6, 8). We, thus, examined whether these responses were downregulated after CD72 ligation in huMCs. Concurrent ligation of CD72 with FcεRI failed to reduce the response observed with FcεRI alone. However, CD72 ligation resulted in a significant reduction in the augmentation of this response by SCF (Fig. 4), demonstrating that the KIT-mediated, but not FcεRI-mediated component of this response could be downregulated by CD72 ligation.

**CD72 ligation induces downregulation of KIT-mediated phosphorylation of signaling molecules**

SCF-induced KIT dimerization results in KIT autophosphorylation, thereby recruiting critical signaling molecules into the receptor signaling complex where they become phosphorylated, allowing their regulation of downstream processes required for mast cell growth and function (6). Such events include recruitment and activation of Src family kinases (SFKs) and downstream signaling cascades regulated by PI3K, MAPKs (MAPKs), and signal transducers and activators of transcription 3 (Stat3) (6). We therefore examined whether the recruitment of SHP-1, after ligation of CD72, was associated with the reversal of these signaling pathways. HuMCs were again stimulated with SCF in the presence or absence of control IgG, BU40, or rCD100 for 15 or 30 mins, then lysates probed for phospho-KIT, phospho-AKT (a surrogate marker for PI3K activation), phospho-SFKs (recognizes both phospho-Lyn and phospho-Fyn), phospho-ERK1/2 MAPKs, and phospho-Stat3.

**CD72 downregulates the growth and the phosphorylation of signaling molecules in HMC1.2 cells**

The HMC1.2 huMC line was established from a patient with mast cell leukemia (17). This cell line harbors gain-of-function mutations in KIT, thus proliferates independently of SCF (5, 18). We examined the effect of BU40 or rCD100 on mutated KIT-induced growth of HMC1.2 cells by cell cycle analysis and by BrdU assay, as for the huMC analysis. HMC1.2 cells were cultured without SCF for 30 min with or without control IgG, BU40, or rCD100, then the cell cycle status of the cells was assessed by flow cytometry. The proportion of HMC1.2 cells in G2/M and S phases after 30 min exposure to rCD100 or BU40 was not reduced compared to that observed with exposure to control IgG (none, 23.6 ± 1.38%; control IgG, 23.3 ± 1.78%; BU40, 20.9 ± 1.93%; rCD100, 21.5 ± 2.36%). We then assessed the effects of rCD100 or BU40 by BrdU assay. In contrast to the cell cycle data, rCD100 or BU40 markedly suppressed the HMC1.2 cell proliferation for 24 h by this assay (Fig. 6).

To address the negative effects of BU40 or rCD100 on HMC1.2 cells, we evaluated the phosphorylation status of CD72 and SHP-1 by immunoprecipitation, and of signal molecules by immunoblotting. Incubation of HMC1.2 cells with BU40 or rCD100 increased the tyrosine phosphorylation of CD72 and SHP-1 and the association between CD72 and SHP-1 even in the absence of SCF stimulation (Fig. 7A, 7C). In addition, we observed the suppressive effects of BU40 or rCD100 on the mutated KIT-induced phosphorylations of KIT, SFKs, and ERK (Fig. 7D). These data, which were compatible with the responses observed in the SCF-stimulated huMCs, show that the aberrant growth of the tumor cell line could also be inhibited on CD72 ligation.

**Discussion**

The ITIM-bearing inhibitory receptor, CD72, has been reported to be expressed on B cells, T cells, NK cells, dendritic cells, and...
CD72 IN HUMAN MAST CELLS

macrophages (13, 28). In this study, we now demonstrate that CD72 is also expressed on huMCs derived from CD34-positive peripheral blood and on huMC lines. This was demonstrated through the presence of mRNA for CD72, and by CD72 protein expression as detected by Western blot and by FACS analysis (Fig. 1A–C). mRNA for CD72 was observed at all stages of development of the huMC cultures examined. However, there was a trend for reduced message in the more mature cultures. Thus, in mature mast cells (8 wk culture), CD72 protein expression was substantially lower than in the HMC 1.2 cells. Regardless, the surface expression as detected by FACS was comparable. A possible explanation for this is that, in HMC1.2 cells, the protein is partly retained in the cytosol (data not shown) due to defective regulation of translocation of CD72 protein to the cell surface after transcription. Differences in CD72 protein expression between the huMCs and HMC1.2 cells may be reflective of the transformed nature of the latter cell type or may reflect an immature phenotype of the transformed cells.

Our data do differ from a previous study where the expression of CD72 by FACS analysis was not detected on huMCs derived from umbilical cord blood (29). However, in that report, the expression of MAFA, which is known to be expressed in mast cells (9), was also not detected. The difference in CD72 expression between the two reports may thus reflect different sensitivities of the Abs used or difference of the origins of the mast cell progenitors. Nevertheless, based on the data presented in this study, CD72 can now be added to the list of inhibitory receptors that are documented to be expressed in mast cells.

The natural ligand for CD72 is recognized to be CD100, thus, an advantage of using CD72 to downregulate SCF-dependent mast cell function is that this can be achieved through interaction of CD72 with its natural ligand. Indeed, in this study, we observed that the cellular responses induced by an anti-CD72 Ab could be mimicked by CD100. Expression of CD100 is reported in B cells, T cells, and neuronal cells (30), but to date has not been reported in mast cells. Our preliminary studies have also failed to detect CD100 expression in primary cultured huMCs and in the HMC1.2 huMC line (data not shown). Regardless, it is possible that interaction between CD72-expressing mast cells and CD100-expressing immune cells may influence mast cell function, as is the case with the interaction among CD72-expressing B cells and CD100-expressing T cells (30). Associations between mast cells and neurons have also been reported (31). Thus, such events may also influence mast cell function via CD72–CD100 interactions. Certainly, our data do provide supportive evidence that ligation of CD72 by CD100, or by means of an agonistic Ab, has the potential to modify KIT-mediated mast cell responses. In this respect, we observed that both rCD100 and an agonistic anti-CD72 Ab downregulated the KIT-dependent growth of huMCs (Fig. 3A), in addition to significantly reducing SCF-induced huMC chemo-taxis, SCF-induced MCP-1 (CCL2) production (Fig. 3B, 3C), and the SCF-enhancement of IgE-dependent degranulation (Fig. 4).

Cellular responses regulated by CD72 have been primarily investigated in B cells and B cell lines (13). However, these studies have sometimes produced conflicting data (13). Although the consensus of studies report that CD72 ligation positively regulates responses in

FIGURE 6. Ligation of CD72 with BU40 or rCD100 suppresses mutated KIT-driven proliferation of HMC1.2 (Brdu assay, n = 3). HMC1.2 cells were incubated for 24 h with control medium, control IgG, BU40, or rCD100 (10 μg/ml, respectively). Incorporation of Brdu into the HMC1.2 cells was assessed using a Brdu cell proliferation assay kit according to the manufacturer’s protocol. The relative values are indicated when the value of control IgG is 100. *p < 0.05, when compared with control IgG.

FIGURE 7. The effects of BU40 or rCD100 on the tyrosine phosphorylation of CD72, the association with SHP-1 with CD72, and on the activation of signaling molecules in HMC1.2 cells. BU40 or rCD100 administration to HMC1.2 cells upregulates (A) the tyrosine phosphorylation of CD72, the association with SHP-1, and (B) the tyrosine phosphorylation of SHP-1. HMC1.2 cells were incubated for 0 or 5 min with control IgG, BU40, or rCD100 (10 μg/ml, respectively) in the absence of SCF. CD72 was immunoprecipitated with anti-CD72 (H-96) or anti–SHP-1 (C-19), and visualized with antiphosphotyrosine 4G10, anti–SHP-1, or anti–Src family kinases (Tyr 416), and β-actin were then assayed by immunoblot analysis. Data are representative from three individual experiments.

FIGURE 8. Proposed model of the effects of CD72–CD100 system on huMCs.
B cells by reversing the inhibitory potential of CD72 (14, 32–39), other studies have revealed that CD72 ligation further increases its inhibitory potential (40). Specifically, CD72 ligation has been reported to induce the proliferation of B cells (32, 33), and to positively regulate CD40-induced (14) and Ag-mediated (36) proliferation of B cells. Furthermore, CD72 ligation by an anti-CD72 Ab was reported to rescue B cell apoptosis mediated by BCR ligation and IgM hypercrosslinking (38, 40). In contrast to these data, which imply that CD72 ligation reverses its inhibitory potential, CD72 expression in B cell line K46 μM and incubation of splenic B cells with an anti-CD72 Ab resulted in downmodulation of BCR-mediated ERK activation and calcium mobilization (40). These data imply that CD72 ligation promotes its inhibitory potential.

These apparently conflicting data have led to the conclusion that CD72 may regulate positive and negative signaling pathways for the regulation of B cell responses and that this may, in part, be related to the stages of B cell development (13). Regardless, the ability of CD72 to regulate cellular responses is dependent on its phosphorylation status, hence its ability to recruit SHP-1, an interaction that is reported to be negatively influenced through its interaction with CD72-bound Grb2 (41). It has been proposed that, in the scenario in which CD72 ligation reverses its inhibitory activity, rCD100 or the agonistic Ab results in dissociation of CD72 from the B cell signaling complex thus reversing BCR-dependent phosphorylation of CD72. In contrast, in the scenario, in which CD72 ligation induces its inhibitory activity, the agonistic anti-CD72 Ab promotes association of CD72 with the receptor signaling-complex thus allowing its phosphorylation and recruitment of SHP-1 (40).

In resting B cells, there appears to be minimal constitutive phosphorylation of CD72 (25). However, in the huMCs, we observed that there was a slight but detectable constitutive phosphorylation of CD72 and its association with SHP-1 in the resting state (Fig. 2). Hence, the possibility exists that CD72 may help regulate the basal activation state of the huMCs. Our data, furthermore, demonstrate that in these cells, ligation of CD72 with either rCD100 or the agonistic Ab BU40 concurrently with KIT activation, results in the activation of necessary events that allow CD72 to inhibit KIT-mediated signaling. Thus, in the case of mast cells, the mode of the responses elicited by rCD100 and BU40 would appear similar to that reported in the splenic B cells (40), which is suggestive of permissive phosphorylation of CD72 by KIT after CD72 ligation. This conclusion was further supported by the enhancement of tyrosine phosphorylation of CD72 observed in the CD72-immunoprecipitates from mast cells incubated with BU40 or rCD100 and triggered through KIT (Fig. 2A, 2B).

Unlike the BCR, KIT possesses inherent catalytic activity that is increased on SCF-induced KIT dimerization. An increase in CD72 phosphorylation was not observed in cells incubated with rCD100 or BU40 in the absence of KIT activation (Fig. 2B). It is likely that the inducible phosphorylation of CD72 observed in the huMCs is directly due to phosphorylation by KIT, contrary to the case in immature B cells. Our data further demonstrated that there was a significant increase in the association of SHP-1 with the tyrosine phosphorylated CD72 (Fig. 2A). SHP-1 has been demonstrated to downregulate KIT signals in vivo (42) and, indeed, we observed that the phosphorylation of SHP-1, which is known to increase its phosphatase activity (26), was elevated in the huMCs (Fig. 2C) and HMC1.2 cells (Fig. 7B) after CD72 ligation. In addition to CD72, SHP-1 has also been shown to be associated with other inhibitory receptors that downregulate KIT-mediated responses in mast cells (12). Thus, we can conclude that the ability of ligated CD72 to inhibit KIT-mediated responses in mast cells is linked to its ability to recruit SHP-1 after its phosphorylation.

SHP-1 dephosphorylates regulatory tyrosine residues on critical proteins that participate in signaling cascades initiated by multiple receptors, including KIT (6). We observed that CD72 phosphorylation led to the suppression of the phosphorylation of KIT, SFKs, and ERK induced by SCF challenge (Fig. 5), but not of AKT or Stat3. Both KIT and SFKs are known to be directly dephosphorylated by interactions with SHP-1 (43–45). Therefore, it is likely that the downregulated phosphorylation of KIT and SFKs induced by coactivation of KIT with CD72 in mast cells was a consequence of the formation of the CD72–SHP-1 complex. It is unclear whether SHP-1 can directly regulate the activation of ERK (46, 47). Therefore, there are two possible explanations for the ERK dephosphorylation observed in the huMCs in response to coactivation of KIT and CD72: 1) The suppressed activation of ERK by CD72 stimulation was mediated directly by the CD72–SHP-1 complex or 2) the suppressed ERK phosphorylation was indirect due to the downregulation of SFKs activity, as ERK phosphorylation is known to be regulated by SFKs (48).

Regardless of whether direct or indirect, the downregulation of the KIT-dependent phosphorylation of KIT, SFKs, and ERK by the interaction of SHP-1 with phosphorylated CD72 would certainly account for the ability of ligated CD72 to downregulate KIT-mediated responses in huMCs. In this respect, in mast cells, the SFKs, Lyn and Fyn, play important roles in KIT-mediated proliferation and chemotaxis (49) and ERK participates in the process of KIT-mediated proliferation and MCP-1 production (50). The downregulation of SCF-induced phosphorylation of SFKs by CD72 would also account for the observed inhibition of SCF-enhanced degradation after CD72 ligation (Fig. 4). The inability of ligated CD72 to decrease the degranulation response induced by FcεRI aggregation alone again points to the requirement of direct phosphorylation of CD72 by KIT to induced inhibitory responses. Taken together, from the previously described conclusions, we can now put together a model of how CD72 may regulate KIT-mediated huMC function (Fig. 8).

In summary, we have presented data that demonstrates that the ITIM-containing inhibitory receptor CD72 is expressed in huMCs and mast cell lines. When ligated either by its natural ligand CD100 or by an anti-CD72 Ab, concurrently with activated KIT, CD72 becomes phosphorylated thereby recruiting SHP-1 resulting in dephosphorylation of critical signaling molecules resulting in downregulation of KIT-mediated mast cell activation. The ability of ligated CD72 to also downregulate the growth of tumor mast cell provides evidence of the potential application of CD72 in mast cell disorders such as mastocytosis.

Disclosures
The authors have no financial conflicts of interest.

References


